Abstract: A storage circuit arrangement for a semi-passive or passive RFID transponder is provided. In prior-art circuit arrangements, storage capacitors are routinely discharged in an undefined fashion via leakage currents for a control mode of the transponder, so that the persistence times depend greatly on the ambient temperature and on existing manufacturing tolerances. It is proposed according to an embodiment to charge a first electrical storage device with a first reference voltage and then to discharge it again in a defined fashion during a time t via discharge device. Advantageously, in addition a storage mode of the first storage device to hold the control mode can be transmitted in a controlled fashion via a switching device to a second storage device with C2<<C1 to shorten a settle time and to accelerate the anticollision.

Abstract: A method for forwarding a request of connection originating from a first telecommunication apparatus (6) allocated to a calling subscriber from a second telecommunication apparatus (6) allocated to a called but absent subscriber to a third telecommunication apparatus (6) shall take into account the interests of the calling subscriber in a particularly great extent. For this purpose, the calling subscriber is offered, according to the invention, to select the third telecommunication apparatus (6).

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

Abstract: The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.

Abstract: In order to allow fuel to be delivered in a controlled manner into a mixing chamber of a carburetor, a needle is displaced towards a needle seat between an open and a closed position in a clocked manner relative to an intake stroke of the engine such that the amount of fuel that flows into the mixing chamber via a fuel duct is controlled in accordance with the rotational speed and the engine load.

Abstract: A device for evaluating a temperature measurement signal of a temperature measurement facility has a modeling unit with a first input for picking up an input signal which is indicative for the temperature measurement signal, a second input for picking up a feedback signal, and an output for outputting an output signal. The output signal can be generated in dependence on the input signal and the feedback signal by using a computational model stored in the modeling unit. The feedback signal (slope) is directly or indirectly dependent on the output signal. Furthermore, an alarm indicator with an evaluation device of this type and a method for evaluating a temperature measurement signal are provided. Alongside this, a computer-readable storage medium and also a program element are described, which contain instructions for carrying out the evaluation method.

Abstract: A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3 and R4, and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8, or an alkyl group optionally substituted with one or more R8 groups; R3, R4, R5, and R6 are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent ?O; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, ha

Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.

Abstract: The invention relates to a metallic effect pigment, which metallic effect pigment has a substantially homogeneous chemical composition comprising at least one metal M and having an average content of oxygen of from 25 to 58 atomic percent, based on the total content of M and oxygen. The invention further relates to a method for the production of said metallic effect pigment.

Abstract: A method and a device are provided, in particular a transponder, for generating a random number by a linear feedback shift register, wherein a first seed is generated by means of a first automaton, a second seed is generated by means of a second automaton, the first and second automata operate using different functional principles, so that the first and second seeds have different properties, and the shift register is reloaded with the first and/or second seed.

Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.

Abstract: A series of mono- and binuclear 4-arylazo-3,5-diamino-pyrazoles which are useful for inhibition of cyclin-dependent kinases (preferably CDK9). Hence they can be used as antimitotic-, pro-apoptotic and antiinflammatory drugs, in particular, in chemotherapy of cancer and asthma, therapy of psoriasis and parasitoses as those caused by fungi or protists, treatment of Alzheimer's disease or as anti neurodegenerative drugs, or to suppress immunostimulation. These compounds are useful in a variety of utilities, including as intermediates in the preparation of flame-retardants, diagnostic reagents and therapeutics, including antivirals and immunosuppressors.

Abstract: Methods, computer readable medium, and systems are provided for moving data objects from a first storage location to a second storage location. A data object may be selected from the first storage location. A first type identifier (ID) and a second type ID may be assigned to the data object. The second type ID may be stored in a second lock object. The first type ID may be stored in a first lock object. The data object may then be stored at the second storage location. The data object may then be deleted from the first storage location. The second type ID may then be deleted from the second lock object.

Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.

Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.

Abstract: A passive, backscatter-based transponder is provided that includes a rectifier that generates an output DC voltage from an input AC voltage for the voltage supply of the transponder, whereby the rectifier includes a first rectifier unit and at least one second rectifier unit. The first rectifier unit and the second rectifier unit are connected in parallel and dimensioned for operation in an identical frequency range.

Abstract: A transponder receives its operating energy from an external source such as a radio signal or a battery. Such transponders are used for example in a vehicle or in a remote sensor. The response range of the transponder is increased by converting the received energy into an operating voltage which in turn is used to generate a function voltage required for performing a current function sequence. The generated function voltage is checked to determine at least one characteristic of the generated function voltage. The determined function voltage characteristic, for example a voltage value directly representing the function voltage, is then used to acknowledge or reject a result of performing the function sequence. Thus, the time duration for performing any current function sequence is flexibly adapted to the current requirements of that function sequence, whereby the power consumption of the transponder is optimally reduced and the response range respectively increased.

Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.

Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.